BriefingFree Daily Briefing

BriefingFree Daily Briefing

Noom

Noom is a Digital Therapeutics company founded in 2008 and based in New York, United States. It has raised $637.8M in total funding, most recently a Series F in 2021 at a $3.7B valuation.

Noom combines psychology-based behavior change content with human coaching and AI to deliver weight management and chronic condition programs via mobile app. Valued at $3.7B (2021). Revenue ~$400M+. Launched Noom Med with GLP-1 prescribing. Laid off staff in 2023-24 restructuring. Filed for IPO in 2022 but delayed.

Noom's consumer brand strength and psychology-first approach established the D2C digital therapeutic model; its pivot into medical weight management (Noom Med, GLP-1s) shows how DTx companies evolve into clinical service delivery.

noom.com Digital Therapeutics

United Statesprivate

At a glance

Total raised

$637.8M

last round series f

Headcount

1k-5k

approximate · public range

Headquarters

New York

United States

Founded

2008

18 years active

Status

Private

Digital Therapeutics

Latest valuation

Funding history

Total raised

$637.8M

Rounds tracked

7

Latest stage

Series F

Latest valuation

$3.7B

Date	Stage	Amount	Valuation	Lead investors
May 25, 2021	Series F	$540M	$3.7B	Silver Lake
May 6, 2019	Series E	$58M	—

Products

Noom Weight
Noom Weight is a psychology-based weight management program delivered via mobile app. It combines daily interactive lessons on behavior change, a color-coded food logging system (green, yellow, orange), step tracking, and optional 1:1 human coaching to help users build sustainable healthy habits. Unlike calorie-counting apps, Noom focuses on the psychological drivers behind eating choices, aiming for long-term habit change rather than quick fixes. Members set personalized goals and receive tailored feedback through the app's AI and coach support.
Noom Med
Noom Med is a comprehensive weight-loss program that pairs prescription GLP-1 medications (such as Wegovy, Zepbound, and Ozempic) with Noom's behavior change framework. Members work with licensed clinicians who prescribe and manage medications when clinically appropriate, while also receiving Noom's psychology-based coaching, food tracking, and habit-building tools. The program is designed to maximize medication effectiveness through lifestyle change and to help members sustain weight loss long-term, potentially without medication.
Noom Mood
Noom Mood is a mental wellness program that applies the same psychology-based behavior change methodology to stress reduction and emotional well-being. The program delivers daily lessons, mood tracking tools, and cognitive reframing exercises to help users understand the connection between thoughts, feelings, and behaviors. It provides personalized content and optional coaching to help users build resilience, manage anxiety, and develop healthier emotional patterns, similar to how Noom Weight approaches eating habits.
Noom GLP-1Rx Program
Noom GLP-1Rx is a medication-focused program offering access to GLP-1 weight-loss drugs (including brand-name and compounded options) integrated with Noom's habit-change methodology. It includes a specialized GLP-1 Companion feature within the app that helps users manage side effects, track progress, and optimize their medication response. The program offers multiple tiers including standard GLP-1Rx and a Microdose GLP-1Rx option designed to minimize side effects while maintaining weight-loss efficacy.